Denali Therapeutics (NASDAQ: DNLI) closes $200M royalty deal after FDA OK

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Denali Therapeutics Inc. reported that on March 27, 2026 it received $200.0 million in gross proceeds at the closing of its previously disclosed synthetic royalty funding agreement with Royalty Pharma. The closing occurred after the U.S. Food and Drug Administration granted accelerated approval to tividenofusp alfa on March 24, 2026.

Positive

$200.0 million upfront funding received at closing of the synthetic royalty agreement with Royalty Pharma, providing significant immediate capital.
Accelerated FDA approval of tividenofusp alfa on March 24, 2026 triggered closing of the funding, marking a major regulatory milestone for the product.

Negative

None.

Insights

Denali secures $200M royalty funding tied to an accelerated drug approval.

Denali Therapeutics has closed its synthetic royalty funding agreement with Royalty Pharma, receiving $200.0 million in gross proceeds on March 27, 2026. This structure typically trades a portion of future product-linked royalties for upfront, non-operating capital.

The funding closed after the U.S. FDA granted accelerated approval to tividenofusp alfa on March 24, 2026, indicating the product has reached a key regulatory milestone. The cash inflow strengthens Denali’s balance sheet, while the economic trade-off is reduced future royalty participation on the covered asset.

Future disclosures may detail how the $200.0 million will support development, commercialization, or other corporate purposes, and the specific royalty percentages and duration that Royalty Pharma will receive under the synthetic royalty agreement.

8-K Event Classification

3 items: 1.01, 2.03, 7.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Key Figures

Gross proceeds received: $200.0 million Tividenofusp alfa approval date: March 24, 2026 Filing form: Form 8-K

3 metrics

Gross proceeds received $200.0 million Received on March 27, 2026 at closing of Royalty Agreement

Tividenofusp alfa approval date March 24, 2026 U.S. FDA accelerated approval preceding funding close

Filing form Form 8-K Describes funding under synthetic royalty agreement

Key Terms

synthetic royalty funding agreement, accelerated approval, Regulation FD Disclosure

3 terms

synthetic royalty funding agreement financial

"related to the synthetic royalty funding agreement between the Company and Royalty Pharma"

A synthetic royalty funding agreement is a financial arrangement where a company receives upfront cash in exchange for promising future payments that are linked to the revenue generated from a specific product or project. For investors, it offers a way to earn returns based on the success of that product without owning it directly, similar to receiving a share of future sales without taking on the risks of production or commercialization.

accelerated approval regulatory

"followed the U.S. Food and Drug and Administration’s accelerated approval of tividenofusp alfa"

Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.

Regulation FD Disclosure regulatory

"Item 7.01 Regulation FD Disclosure. Royalty Agreement Closing and Funding"

Understanding 8-K Material Events →

03/31/2026 - 08:30 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

March 27, 2026

Denali Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38311

46-3872213

(State or other jurisdiction of

(Commission

(I.R.S. Employer

incorporation)

File Number)

Identification No.)

161 Oyster Point Blvd.

South San Francisco, California 94080

(Address of principal executive offices, including zip code)

(650) 866-8547

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last reports)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol (s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	DNLI	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information contained in Item 1.01 of the Form 8-K filed by Denali Therapeutics Inc. (the “Company”) on December 4, 2025 related to the synthetic royalty funding agreement between the Company and Royalty Pharma (the “Royalty Agreement”), and the information contained in Item 7.01 below, is hereby incorporated by reference into this Item 2.03 in its entirety.

Item 7.01 Regulation FD Disclosure.

Royalty Agreement Closing and Funding

On March 27, 2026, the Company received $200.0 million in gross proceeds in connection with the closing of the transactions under the Royalty Agreement. The closing followed the U.S. Food and Drug and Administration’s accelerated approval of tividenofusp alfa on March 24, 2026.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


		DENALI THERAPEUTICS INC.

Date:	March 31, 2026	By:	/s/ Alexander O. Schuth
			Alexander O. Schuth, M.D.
			Chief Operating and Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Denali Therapeutics (NASDAQ: DNLI) closes $200M royalty deal after FDA OK